Stock PLSE PULSE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-17 pm EDT 		5-day change 1st Jan Change
7.47 USD -3.98% Intraday chart for Pulse Biosciences, Inc. +0.81% -38.97%
Apr. 01 Sector Update: Health Care Stocks Slide Late Afternoon MT
Apr. 01 Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sector Update: Health Care Stocks Slide Late Afternoon
MT
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans
MT
Transcript : Pulse Biosciences, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
BU
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Pulse Biosciences Announces Plans to Initiate a Rights Offering
BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
BU
Sector Update: Health Care Stocks Ease Late Afternoon
MT
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System
MT
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
BU
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System
CI
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY
AQ
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study
CI
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
BU
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday
MT
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp
MT
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp
CI
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.